HOME >> MEDICINE >> NEWS
Possible treatment found for 'chemobrain'

Patients who take medication for cancer often find themselves with a new problem when their treatment ends.

It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.

Symptoms of chemobrain can also include lack of focus, inability to organize daily activities, mental confusion, memory loss and decreased mental clarity.

It's estimated that chemobrain occurs in as many as 99 percent of breast and ovarian cancer patients receiving chemotherapy or radiation treatments. Sixty-one percent of these patients continue to experience fatigue and memory problems long after their cancer treatment has stopped.

Now, researchers led by the University of Cincinnati's (UC) Elyse Lower, MD, report a possible new treatment for the problem using the drug dexmethyphenidate (d-MPH).

Dr. Lower, professor of hematology/oncology at UC College of Medicine, recently described the encouraging results of a 14-month, multi-center, Phase 2 study of d-MPH to the annual meeting of the American Society of Clinical Oncology.

The 154 cancer survivors at 21 medical centers showed significant reduction in fatigue and improvement in memory when treated with dosages of 10 mg to 50 mg of d-MPH per day, Dr. Lower said, when compared with a control group receiving a placebo.

All the patients, who had a median age of 53 years, had completed at least four cycles of chemotherapy at least two months before the study began. Ninety percent of them were female (76 percent with breast cancer and 14 percent with ovarian cancer), 79 percent were white and 9 percent were African-American.

"The study showed that up to 50 mg a day of d-MPH is safe and effective for relieving chemobrain in adult cancer patients," said Dr. Lower, "and it should be considered as a treatment."

One of the study participants, Marilyn Metz, had undergone radiation and chemotherapy in 2001 to t
'"/>

Contact: Sheryl Hilton
sheryl.hilton@uc.edu
513-558-4561
University of Cincinnati
7-Jun-2005


Page: 1 2

Related medicine news :

1. Possible new breast cancer gene
2. Possible predictors of relationship violence
3. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
4. Spot on treatment for acne
5. New treatment boosts muscle function in myasthenia gravis
6. New treatment effective in counteracting cocaine-induced symptoms
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Preventive treatments in elderly people needs rethinking
9. Osteoporosis screening and treatment may be cost-effective for selected older men
10. Quality of treatment guidelines
11. Green tea holds promise as new treatment for inflammatory skin diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... ... November 30, 2016 , ... ... clinical research community that the FDA Binding Guidance goes into effect next month. ... formats listed in the FDA Data Standards Catalog. The current FDA Data Standards ...
(Date:11/30/2016)... ... November 30, 2016 , ... U.S. Security Associates (USA) ... services based in Richmond, Virginia. The acquisition further strengthens USA’s capabilities within ... security services and prides itself on 100% client-retention to the healthcare industry. In ...
(Date:11/30/2016)... Philadelphia, PA (PRWEB) , ... November 30, 2016 ... ... and pharmaceutical organizations to build intelligent, connected applications, announces today that it has ... (HITRUST). , CloudMine, has been self-certified as compliant with the HITRUST CSF ...
(Date:11/30/2016)... ... November 30, 2016 , ... Staying on top ... deductibles, more restrictive lists of healthcare providers and soaring drug costs. To help ... estimator tools, offered by New York health plans. These tools, which are ...
(Date:11/30/2016)... Linda, Ca (PRWEB) , ... November 30, 2016 , ... ... in Best in Biz Awards, the only independent business awards program judged by members ... progress as it drives revenue and growth, while maintaining partner relations. In 2015 LabRoots ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 CVS Health ... annual Analyst Day in New York City on Thursday, December 15, 2016, ... Health leadership team will provide an in-depth review of ... shareholder value. The company will also discuss 2017 earnings ... video webcast of the event will be broadcast simultaneously ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... Extremity Braces & Support) is Expected to Gain a Significant ... Prone to Orthopedic Ailments  ... , , According ... Market Study on Medical Implants Sterile Packaging: Clamshell Product Type ...
(Date:12/2/2016)...   CytoSorbents Corporation (NASDAQ: CTSO ), ... approved CytoSorb ® cytokine adsorber to treat deadly ... that Dr. Phillip Chan , Chief Executive Officer, ... Main Event investor conference held from December 6 ... Boulevard Hotel in Los Angeles, California ...
Breaking Medicine Technology:
Cached News: